

25 convenient experimental system for analysing the toxicity of ectopically expressed
26 human disease genes. However, the association between REP and axonal degeneration,
27 an early sign of ND, remains unclear. To address this question, we developed a method
28 to evaluate axonal degeneration by quantifying the number of retinal R7 axons in
29 *Drosophila*; however, it requires expertise and is time-consuming. Therefore, there is a
30 need for an easy-to-use software that can automatically quantify the axonal degeneration.
31 **Result:** We created MeDUsA (a ‘method for the quantification of degeneration using fly
32 axons’), which is a standalone executable computer program based on Python that
33 combines a pre-trained deep-learning masking tool with an axon terminal counting tool.
34 This software automatically quantifies the number of axons from a confocal z-stack image
35 series. Using this software, we have demonstrated for the first time directly that axons
36 degenerate when the causative factors of NDs (α Syn, Tau, TDP-43, HTT) were expressed
37 in the *Drosophila* eye. Furthermore, we compared axonal toxicity of the representative
38 causative genes of NDs and their pathological alleles with REP and found no significant
39 correlation between them.

40 **Conclusions:** MeDUsA rapidly and accurately quantifies axons in *Drosophila* eye. By
41 simplifying and automating time-consuming manual efforts requiring significant
42 expertise, it enables large-scale, complex research efforts on axonal degeneration, such
43 as screening to identify genes or drugs that mediate axonal toxicity caused by ND disease
44 proteins.

45

46 **Keywords:**

47 Axonal degeneration, Quantification, Standalone program, *Drosophila*,

48 Neurodegenerative disease

49

50 **Background:**

51 Neurodegenerative diseases (NDs) are disorders in which certain groups of neurons in
52 the brain and spinal cord involved in cognitive and motor function are gradually lost.
53 Molecular genetic studies have identified causative genes and risk factors and elucidated
54 the mechanisms of pathogenesis at the molecular level. These findings revealed that
55 structural defects and aggregation of disease-associated proteins underlie
56 neurodegenerative processes [1]. It has become available to examine the effects of novel
57 mutations found in human diseases like NDs, whether they result in the loss of gene
58 function or gain of toxic function, using various model organisms. Among them,
59 *Drosophila* has various advantages as a neuronal disease model. For example, 1) gene
60 function can be analysed without strongly considering the compensation of gene function
61 by duplication since there are relatively few duplicated genes in the genome; 2) research
62 sample sizes can be large because individuals are small, inexpensive and easy to breed;
63 3) the short life cycle allows rapid genetic analysis and 4) the organism has a compact
64 brain, making it possible to analyse at the level of neural circuitry and behaviour
65 necessary for higher functions such as learning, memory and sleep. Taking advantage of
66 these features, *Drosophila* is widely used in studies on human diseases. Further, it has
67 been reported that the expression of a human disease-associated protein in *Drosophila*
68 induces toxicity even in flies [2–6], demonstrating the conservation of molecular
69 mechanisms between humans and flies.

70 Trinucleotide repeat disorders are human diseases caused by the expansion of
71 CAG repeats in the protein-coding regions of causative genes. Spinocerebellar ataxia type
72 3 (SCA3), also known as Machado-Joseph disease, is a neurodegenerative disease caused

73 by repeated elongation of glutamine. In *Drosophila*, the expression of these extended
74 polyglutamine repeats not only formed inclusion bodies similar to those in humans, but
75 also caused degeneration [2]. CAG repeats are also found in Huntingtin (HTT), the gene
76 responsible for Huntington's disease, which is another autosomal dominant
77 neurodegenerative disease. In experiments in which polyglutamine-extended HTT was
78 expressed in the photoreceptors of *Drosophila*, inclusion bodies formed and the
79 polyglutamine-extended HTT induced neurodegeneration [3]. Additionally, in
80 Parkinson's disease (PD), a neurodegenerative disorder characterised by the loss of
81 dopaminergic neurons in the substantia nigra, formation of Lewy bodies and impaired
82 motility, expression of the causative gene synuclein alpha (SNCA) in *Drosophila* caused
83 the loss of dopaminergic neurons, the formation of fibrous intraneuronal inclusions
84 containing Alpha-synuclein (α Syn) and motor dysfunction [4]. Furthermore, the
85 expression of the microtubule-associated protein Tau, which is involved in Alzheimer's
86 disease, in all neurons of *Drosophila* led to the observation of progressive
87 neurodegeneration [5]. Thus, *Drosophila* models expressing human disease-causing
88 genes can reproduce the characteristics of human diseases, thereby enabling powerful
89 genetic approaches to study various NDs such as polyglutamine disease, synucleinopathy
90 and tauopathy. Using these ND models, large genetic screens can be performed to explore
91 unknown protein networks in which disease-causing proteins interact. The homologues
92 of the candidate network members can then be identified in the human genome to
93 determine whether they are susceptibility genes of the disease of interest. In one example
94 of a disease study of amyotrophic lateral sclerosis (ALS), genetic screening using this
95 experimental paradigm identified that ATXN2 is involved in ALS pathogenesis
96 [7]. Further, suppression of the ATXN2 *Drosophila* homologue reduced the toxicity of

97 TDP-43, which is a DNA/RNA-binding protein implicated in several NDs. The discovery
98 of ATXN2 accumulation in the spinal cord of human ALS is but one example revealed
99 using this screening approach in *Drosophila*.

100 The rough eye phenotype (REP), which is frequently used to investigate genetic
101 interactions in *Drosophila*, is also used in disease research as a convenient and quick way
102 to assess the toxicity of ectopically expressed genes. The phenotypic assay uses the
103 Gal4/UAS method [8] to evaluate the toxicity of a gene of interest by expressing it
104 specifically in the eye using the eye-specific *Gal4*, *GMR-Gal4* and observing eye
105 structure. In fact, this fly eye assay has identified several modifiers that inhibit or enhance
106 the toxicity caused by pathogenic factors such as Tau [9–11], α Syn [12–15], TDP-43
107 [16,17] and polyglutamated HTT [18–20]. Moreover, drug screenings can be performed
108 by adding compounds to fly food, and compounds that reduce disease toxicity can be
109 identified [21,22]. Although REP has been evaluated qualitatively in most previous
110 studies, several research groups have recently reported methods for the quantitative
111 evaluation of REP [23,24]. However, it remains unclear whether REP reflects
112 neurodegeneration completely as the formation and geometric defects of cell clusters are
113 assessed only within the ommatidium, which contains cone and pigment cells. To assess
114 neurodegeneration more fully in *Drosophila*, several other parameters related to
115 neurodegeneration, as measured by protein aggregation number, vacuolar size and
116 number and retinal thickness, have been previously developed [25]. However, these
117 systems also indirectly observe neurodegeneration, and therefore, a direct quantitative
118 method for accurately measuring neurodegeneration is required.

119 Axonal degeneration is a representative pathology of neurodegeneration, and
120 the magnitude of neurodegeneration can be accurately evaluated by its quantification. To

121 date, there are few methods for quantifying axonal degeneration [26,27]. Further, they
122 are time-consuming, requiring the manual quantification of axonal number or depend on
123 the expertise of experimenters to accurately classify the degree of degeneration. However,
124 biological images contain noise, and variable signal intensities are often observed among
125 samples. Additionally, the three-dimensional (3D) structure and angle are never uniform
126 between images. Thus, to recognise the semantic region from diverse image data, the eye
127 of a trained researcher can flexibly and accurately extract specific phenomena to be
128 analysed, but such time-consuming methods are not suitable for screening to identify
129 genes or compounds that modify the pathology and requires quantifying large numbers
130 of samples. Therefore, robust image processing systems other than the human eye are
131 required to evaluate axonal degeneration simply and quickly. In recent years, image
132 processing technology has made remarkable progress, especially the development of
133 deep-learning technology using convolutional neural networks (CNNs), which has
134 greatly advanced the field of image recognition, and is also true in the field of biological
135 images [28]. In addition, although conventional image processing can extract signal
136 regions, it is difficult to extract semantic regions, but CNN has demonstrated high
137 performance in semantic domain segmentation. In particular, U-Net [29] is an
138 architecture of CNNs designed for biological image analysis, and U-Net and its derived
139 architectures have been used for segmentation tasks in the area of biological image
140 analysis with great success [30–33].

141 In an accompanying study, we developed a novel method to directly quantify
142 axonal degeneration using R7, a photoreceptor neuron type in *Drosophila*, as a model
143 [34]. In this method, axon terminals are manually excised from the confocal microscope
144 z-stack image series, and degeneration is quantified by manual counting the number of

145 axon terminals. This allowed quantifying even minor axon losses; therefore, even very
146 early stages of axonal degeneration phenomena. Nonetheless, its throughput was not
147 sufficient for larger scale screens. To automate the method, we established here a novel
148 software package called ‘method for the quantification of degeneration using fly axons’
149 (MeDU_sA) by combining deep learning with a Python-based counting system. Using this
150 software, we assessed the effects on axons among the causative genes of several NDs and
151 found that they exhibited axonal degeneration. Additionally, no significant correlation
152 was detected between the number of axons and the REP. MeDU_sA provides direct and
153 rapid quantitation of axonal degeneration in *Drosophila*, making it a powerful tool that
154 can be used in disease and developmental studies.

155

156 **Results:**

157 **Rough eye phenotype is insufficient to speculate on gene effects in axonal** 158 **degeneration**

159 The Rough eye phenotype (REP) assay has been extensively used to study
160 neurodegenerations (NDs) [35]; however, there is uncertainty whether REP accurately
161 reflects axonal degeneration. We performed a modifier genetic screening designed to
162 identify genes that modulate the toxicity of TDP-43 by observing retinal and axonal
163 degeneration phenotypes. The *Drosophila* photoreceptors R7 and R8 project their axons
164 directly from the compound eye retina through the primary optic ganglion lamina to the
165 secondary optic ganglion medulla (Fig. 1A). For this screening, a fly line with eye-
166 specific expression of TDP-43^{G298S}, which is an ALS-associated mutation of TDP-43 [36],
167 using *GMR-Gal4* [37,38] was generated. These flies were crossed with 99 candidate RNA
168 interference (RNAi) lines (Fig. 1B; see Materials and Methods). In the first screening

169 round, we observed the eye phenotype because the eye-specific expression of TDP-
170 43^{G298S} causes REP as previously reported [39]. As a result, 14 of 99 RNAi lines were
171 identified that suppress REPs (Fig. 1B, 1C). Next, we evaluated the axonal degeneration
172 of R8 retinal axons, as the second screening round (Fig. 1B, 1C). To quantify the axonal
173 degeneration, we calculated the ratio of degenerated axons in the part of the optic lobe
174 that is easy to observe each axon. We classified an axon as degenerated when the axon
175 was fragmented. Eye-specific expression of TDP-43 displayed axonal degeneration of R8
176 axons one day after eclosion (Fig. 1C). We expected that REPs identified in the first
177 screening round would be consistent with the morphology of the R8 axons under the
178 assumption that RNAi lines which suppressed REPs rescued the axonal degeneration.
179 Surprisingly, the REP results did not always match those of axonal degeneration.
180 Knockdown of *Dsk*, a neuropeptide-encoding gene identified in only crustaceans and
181 insects, in the background of TDP-43 expression strongly suppressed REP; however, *Dsk*
182 knockdown significantly promoted axonal degeneration (Fig. 1C; quantified in 1D). In
183 addition, the knockdown of 10 genes did not affect axonal degeneration, whereas 3 genes
184 (*mle*, *faf* and *caz*) rescued the degeneration (Fig. 1C; quantified in 1D). Thus, although
185 the REP assay is a simple and powerful method for assessing toxicity, it is insufficient to
186 evaluate axonal degeneration. Further, the quantitative method we used to assess
187 degeneration in this screening was also insufficient for precise quantification because it
188 was a subjective determination whether an axon was degenerated (i.e. fragmented) or
189 intact. Other limitations include the fact that axons which are completely lost cannot be
190 counted and all R8 axons were not counted from the dorsal view due to limits of the
191 confocal microscope scanning time and depth at which the sample could be viewed
192 cleanly. Additionally, depending on the person performing the method and region being

193 quantified, the results would display a high degree of variability. Therefore, we developed
194 an automatic system, MeDUsA for the unbiased quantitative evaluation of axonal
195 degeneration in *Drosophila*.

196

197 **The process flow for using MeDUsA**

198 To quantify R7 axons using MeDUsA, the first step is to prepare samples of the
199 *Drosophila* brain (Fig. 2A and 2B). Dissection and immunostaining were performed as
200 previously described [34,40] .

201 In the second step, axon termini were identified and quantified. For this purpose,
202 we developed MeDUsA to enable non-experts to accurately evaluate axonal degeneration
203 and to save time. MeDUsA utilises a combination of tools available in Python that allows
204 the task of masking axons to be performed by pre-trained deep learning, followed by
205 automatic counting of axon terminals after masking. This software enables researchers to
206 quantify the number of R7 axons readily and quickly, taking 50 seconds per sample on a
207 general desktop workstation (CPU: Intel Core i7 9800X 3.8 GHz, RAM: DDR4 128 GB).

208 To create a model that generates a mask of the surface area, we trained a 2D-
209 U-Net architecture (Fig. 2C). However, to determine the surface area, it is necessary to
210 infer it from the axon terminal signals in the sparsity, and there are areas where it is
211 difficult to determine the surface area with a single z-slice. Therefore, we trained the 2D-
212 U-Net to generate a surface mask of three slices by inputting three slices as three channels,
213 including the slice before and after the slice of interest. Then, during inference, only the
214 mask of the centre slice was used. The training and testing datasets included both normal
215 and abnormal images. A total of 16,114 images in 199 samples were used for training and

216 1,375 images in 16 samples were used for testing. By using three channels, the dice score
217 improved from 0.815 to 0.847 compared to using a single channel.

218 After mask generation and axon terminal extraction, the number of axonal
219 terminals was counted automatically (Fig. 2D). To do this, we first filtered the regional
220 maxima to remove background, followed by binarisation using adaptive thresholding.
221 The surface area was then extracted using mask images. We performed a Euclidean
222 distance transformation to obtain peaks, which were used as seeds to perform 3D
223 watershed to obtain each axon terminal candidate. Finally, candidates below 20 voxels
224 (equivalent to a radius of about 1.68 μm) were eliminated, and the remaining ones were
225 counted as axon terminals. This process was fully automated and allowed us to stably
226 detect axon terminals without adjusting parameters for each sample.

227

228 **Ectopic expression of causative genes of NDs causes axonal degeneration in R7** 229 **neurons**

230 Using our MeDUsA, we evaluated the effect of mutations in proteins responsible for NDs
231 on axonal degeneration in *Drosophila*. We expressed either wild-type or well-known
232 mutant alleles of human causative genes for neurodegenerative diseases (αSyn , Tau,
233 TDP-43 and HTT) in photoreceptor axons using *GMR-Gal4* and predicted the number of
234 axonal terminals in 1-day-old adults. The ectopic expression of wild-type αSyn , which is
235 a causative gene of PD [41], in photoreceptor axons did not show a significant reduction
236 in axonal number compared to control, whereas the expression of A53T-mutated αSyn , a
237 well-known pathogenic allele associated with familial PD [42], caused a significant
238 reduction in the number of axons compared to control (Fig. 3A–C; quantified in 3K).
239 However, there was no significance between wild-type and A53T-mutated αSyn . Next,

240 we found that expression of wild-type Tau (Tau^{WT}), which is implicated in Alzheimer's
241 disease, caused significant axonal degeneration, and the expression of Tau with the
242 R406W mutation, which is a missense mutation identified in families diagnosed with
243 frontotemporal dementia and parkinsonism linked to chromosome 17 [43], enhanced the
244 degeneration (Fig. 3D, 3E; quantified in 3K). Interestingly, the expression of Tau with
245 the S2A mutation, a mutation with impaired phosphorylation capabilities, significantly
246 suppressed axonal degeneration compared to Tau^{WT} (Fig. 3F), indicating that
247 phosphorylated Tau exhibits toxicity. Next, we evaluated the expression of both wild-
248 type and A315T-mutated [44] TDP-43, which has been identified as the major disease
249 protein in ALS, in photoreceptor axons, and found that both displayed axonal
250 degeneration, although degeneration was milder in the A315T mutant than in wild-type
251 TDP-43 (Fig. 3G, 3H; quantified in 3K). Finally, we found that ectopic expression of
252 wild-type HTT (HTT^{Q0}), the causative gene of Huntington's disease, did not cause axonal
253 degeneration, whereas the expression of HTT with a pathogenic polyQ tract of 128
254 repeats (HTT^{Q128}) significantly reduced the number of R7 axons (Fig. 3I, 3J; quantified
255 in 3K). These results show that the ectopic expression of causative genes of human NDs
256 induced axonal degeneration in *Drosophila*, and well-known pathogenic mutations
257 enhanced degeneration, except for TDP-43. Our findings demonstrate that the toxicity of
258 various human disease causative proteins can be reliably assessed across species using
259 our quantitative axonal degeneration fly model.

260 To evaluate the performance of MeDUsA, we quantified the axonal number
261 of the same sample set manually (Fig. 4A). This manual method enabled us to carry out
262 precise quantification of axonal number; however, manual quantification is time-
263 consuming and several parameters have to be adjusted for each sample to detect axon

264 terminals. The MeDUsA measurements were lower than the manual measurements (Fig.
265 4B). This is due to the severity of the setting (Fig. 2D) for recognising the axon terminal
266 in automated quantification. If the setting is further set loose, the false positive count
267 increases. At present, this is the limitation of the MeDUsA. Nevertheless, the system
268 showed a quadratic weighted kappa score (κ_2) of 0.724 and a significantly strong
269 positive correlation with manual counting (individual values, $R^2 = 0.887$, $p < 0.001$, Fig.
270 4C; mean value per genotype, $R^2 = 0.944$, $p < 0.001$, Fig. 4D). Taken together, these
271 findings demonstrate that MeDUsA automatically and rapidly counts axonal number in
272 a preparation accessible for genetic screening.

273

274 **REP does not match the axonal degeneration phenotype**

275 Next, we evaluated the correlation between axonal degeneration phenotype and the REP.
276 To quantify REP severity, we used Flynotyper that calculates the phenotypic score from
277 the disarray of the ommatidia [24]. We expressed the same set of causative genes for NDs
278 in the eye using *GMR-Gal4* as in axonal degeneration experiments and quantified the
279 degree of phenotypic severity of eye phenotypes in 1-day-old adults. We found that the
280 expression of either the wild-type or pathogenic allele of α Syn did not significantly
281 increase the phenotypic score compared to control (Fig. 5A–C; quantified in 5K),
282 although the expression of the pathogenic alleles of α Syn caused axonal degeneration
283 (Fig. 3K). In contrast, REP severity was consistent with the reduction of axonal number
284 when the wild-type and mutant alleles of Tau were expressed (Fig. 5D–F; quantified in
285 5K). Wild-type and R406W-mutated Tau, both of which caused axonal degeneration,
286 showed a significantly increased phenotypic score, whereas the S2A mutation did not
287 display any reduction in axonal number nor corresponding score increase. Similar to α Syn,

288 we found that TDP-43 expression showed an obvious discrepancy between the two
289 phenotypes. As described earlier, wild-type TDP-43 is more toxic than A315T-mutated
290 TDP-43 on axonal degeneration (Fig. 3K). However, the A315T mutation caused a
291 significant increase in the REP score compared with wild-type TDP-43 (Fig. 5G, 5H;
292 quantified in 5K). HTT expression also exhibited differences between axon and eye
293 phenotypes. In contrast to axonal degeneration phenotypes, the ectopic expression of
294 HTT^{Q128} did not cause REPs (Fig. 5I, 5J; quantified in 5K). Finally, we determined the
295 correlation between the average axonal number and average phenotypic score of rough
296 eye in each genotype, and found a negative correlation, but the correlation was not
297 statistically significant ($R = -0.467$, $p = 0.174$). Taken together, our findings show that
298 REP scoring is not exactly consistent with the degree of axonal degeneration.

299

300 **Discussion:**

301 We recently developed a method that precisely quantifies the axonal number of retinal
302 R7 neurons by creating a mask which extracts the axon terminals [34]. In the present
303 study, we developed and tested MeDUa, a software that automatically creates masks
304 and counts axon terminals using a combination of deep learning and Python (Fig. 2). By
305 using this software, the number of R7 axons can be automatically quantified easily and
306 quickly from confocal images. Conventionally, REP is frequently used to assess
307 neurotoxicity in fly studies because it does not require special equipment and can be
308 readily performed; however, we found that the severity of REP is not always consistent
309 with axonal toxicity (Fig. 3 and Fig. 5). Also conditions that induce sporadic progressive
310 axonal degeneration of R7 are not accompanied by cell death [34]. Therefore, we propose
311 that ND research can be conducted more efficiently by combining REP with our method

312 when the focus is axonal degeneration. Although several models for evaluating axonal
313 degeneration in *Drosophila* have been reported [26,27,34], they are technically difficult
314 and exceedingly time-consuming to evaluate axonal degeneration in large-scale
315 experiments such as screening as the evaluation of degeneration in these models is
316 subjective or require manual measurement. However, by using MeDUsA, it is not only
317 possible to identify factors and chemical compounds that inhibit axonal degeneration in
318 the fly model of ND by screening but also to easily evaluate axonal toxicity of new or
319 undiagnosed variants of pathological proteins of ND.

320 According to our modifier screening using REP to identify genes that suppress
321 TDP-43^{G298S} toxicity, we identified 14 candidate genes. Further investigation focused on
322 axonal degeneration showed that the knockdown of three genes (*mle*, *caz* and *faf*)
323 suppressed toxicity, whereas *Dsk* knockdown promoted it (Fig. 1C, 1D). *Dsk* encodes the
324 cholecystokinin-like neuropeptide Drosulfakinin and has been reported to be involved in
325 feeding behaviour, aggression and larval avoidance [45–48]. A previous study reported
326 that *Dsk* is also involved in synaptogenesis in the neuromuscular junction in cooperation
327 with a putative cholecystokinin-like receptor [49]. Studies in mouse models have shown
328 that the pathogenic form of TDP-43 has harmful effects on synapses. For example,
329 hyperexcitability has been observed [50] and spine density has been reduced [51].
330 Therefore, our results suggest that *Dsk* reduction causes synapse dysfunction and make
331 axons fragile, whereby axonotoxicity of TDP-43^{G298S} is enhanced. Named by its male-
332 specific lethal phenotype in loss-of-function mutants, *mle* (*maleless*) encodes an RNA
333 helicase and is a member of the Male-Specific-Lethal transcription complex, which is
334 involved in dosage compensation in males [52]. The homologue of *mle* in human, *DHX9*,
335 was reported to encode a TDP-43–interacting protein [53]. Furthermore, a previous study

336 reported in a fly model that knockdown of *mle* exacerbated neurodegeneration caused by
337 the expression of expanded UGGAA, which is considered responsible for spinocerebellar
338 ataxia type 31 (SCA31), whereas overexpression of wild-type TDP-43 suppressed
339 expanded UGGAA-induced toxicity [39]. Thus, *mle* may be involved in the RNA-
340 dependent toxicity of TDP-43. *caz* (*cabeza*), which encodes a RNA-binding protein, is a
341 fly homologue of FUS/TLS, which is another major causative gene for ALS. Physical
342 interactions between human FUS/TLS and TDP-43 have been reported in mammalian
343 cultured cells [54,55], and it has been suggested that FUS/TLS is genetically located
344 downstream of TDP-43 in fly and fish models [56,57]. Therefore, the attenuation of
345 axonal degeneration by *caz* knockdown may be due to the suppression of excess unknown
346 downstream factors of TDP-43 or *caz* itself or both. The influence of *faf* (fat facets),
347 which encodes a deubiquitylated enzyme and is a fly homologue of *USP9X*, on
348 neurodegeneration varies among fly ND models. Lee et al. reported that FAF enhanced
349 the toxicity of amyloid precursor protein (APP) and A β -42. The co-expression of FAF
350 with either APP or A β -42 enhanced REP and knockdown of *faf* suppressed the post-
351 synaptic toxicity of APP and A β -42 [58]. Another group revealed that reduced levels of
352 *faf* enhanced retinal toxicity of HTT [19]. As FAF deubiquitinates different substrates in
353 these diseases, it may be reflected in the different effects on the toxicity of causative
354 proteins of the ND. Further analysis of these genes would shed light on the molecular
355 mechanisms underlying axonotoxicity by TDP-43^{G298S}.

356 Using the automatic quantification method developed in this study, we
357 evaluated the axonal effects of several representative causative factors of NDs, including
358 α Syn, Tau, TDP-43 and HTT (Fig. 3). Although the pathological significance of these
359 causal factors has been examined in various model organisms, including fly model, few

360 studies have directly visualised and quantitatively evaluated axonal degeneration such as
361 that demonstrated in this study using MeDUsA. Our findings show that MeDUsA is
362 highly extensible and can be used in different NDs to demonstrate how a causative gene
363 affects axonal degeneration.

364 *SNCA* encodes α Syn, which is highly localised at the pre-synaptic terminal, and
365 is thought to mediate the regulation of synaptic function [59]. Studies using post-mortem
366 brains and primary neurons from patients with PD suggest that α Syn aggregates in axons
367 and causes degeneration, resulting in impaired neuronal function that is propagated to the
368 cell body and leads to neuronal death [60,61]. The A53T mutation is a well-known toxic
369 mutation of α Syn that aggregates more rapidly and forms fibrils than wild-type, and many
370 studies using animal models and induced pluripotent stem (iPS) cells derived from
371 patients with PD have reported high neurotoxicity [62–64]. In our study, a significant
372 reduction in the number of axons was observed between control and α Syn^{A53T}-expressed
373 flies, but no statistically significant difference was observed between wild-type and A53T
374 (Fig. 3K). A possible reason for the non-significant difference is that quantification was
375 performed too early (1-day-old adult), and differences between the wild-type and A53T
376 mutation may be observed if quantified several weeks after eclosion.

377 Tau is a microtubule-associated protein that binds to microtubules and
378 maintains their stability in neurons. In tauopathies, Tau is thought to be dissociated from
379 microtubules by excessive phosphorylation and aggregate, causing a dying-back pattern
380 of neurodegeneration [65]. Although several studies have reported increased toxicity with
381 the R406W mutation, a change in the phosphorylation status remains controversial.
382 Studies using *in vitro* and patient-derived iPS cells have reported that R406W mutant *tau*
383 is less phosphorylated than wild-type *tau*, whereas excessive phosphorylation has been

384 observed in both murine model and post-mortem patient brain [66–69]. Although
385 previous studies reported that overexpression of Tau^{R406W}, which was used in this study,
386 displayed high toxicity in REP compared to Tau^{WT} in *Drosophila* [5,70], it may be due
387 to positional effects of the UAS insertion site [71]. Consistent with previous reports, we
388 found that Tau^{R406W} overexpression exerted a more toxic effect on axons than Tau^{WT}
389 overexpression (Fig. 3K).

390 TDP-43 is a highly conserved 43 kDa RNA-binding protein that is a main
391 component of ubiquitinated aggregation in the neurons of patients with ALS and
392 frontotemporal lobar degeneration (FTLD) [72]. Numerous studies that have investigated
393 the physiological function of TDP-43 have revealed that TDP-43 is involved in various
394 aspects of RNA metabolism, and these disturbances may be responsible for the
395 pathogenesis of ALS and FTLD [73]. In many model organisms, both overexpression and
396 loss-of-function of TDP-43 result in reduced longevity and motor function [74–77]. The
397 overexpression of wild-type TDP-43 in *Drosophila* mushroom body neurons of the
398 olfactory memory centre causes axonal degeneration [78], whereas the effects of the
399 A315T mutation on TDP-43 toxicity are controversial in *Drosophila*. Guo et al. reported
400 that TDP-43^{A315T} was more toxic to motor neurons than TDP-43^{WT}, whereas Patricia et
401 al. reported that TDP-43^{WT} showed severe toxicity compared to TDP-43^{A315T}, except for
402 larval locomotor activity [79,80]. In our present result of retinal R7 axons, we found that
403 wild-type TDP-43 showed higher axonal toxicity than the A315T mutation (Fig. 3K).
404 Although TDP-43 is primarily expressed in the nucleus, the aggregation of TDP-43 in the
405 cytoplasm causes toxicity. As wild-type TDP-43 may be increased in the cytoplasm if it
406 is overexpressed, it is important to realise that differences in expression levels in each

407 experimental system may contribute to differences in the respective results. TDP-43 may
408 also have different toxic effects on different neuronal cell types.

409 In Huntington's disease, CAG repeat expansion of *HTT* produces abnormal
410 RNA and protein, leading to neuronal dysfunction and eventual cell death. The normal
411 allele of *HTT* contains fewer than 26 CAG repeats, whereas 36 repeats or more are
412 associated with Huntington's disease [81]. A study using a mouse model of HD and
413 human patients indicated that the degeneration of the callosal axon was seen before
414 symptoms were observed, suggesting that the mutant HTT caused dying-back
415 neurodegeneration [82]. Furthermore, CAG repeat number-dependent cytotoxicity has
416 been reported in *Drosophila* [83]. In this study, as in previous reports, HTT^{Q128} showed
417 axonal toxicity but HTT^{Q0} did not (Fig. 3K).

418 Axonal degeneration is observed not only in NDs but also in Wallerian
419 degeneration (WD), which is the axotomy-induced distal degeneration of an axon,
420 causing a decline in neuronal function. The mechanisms of axonal degeneration in NDs
421 and WD are partly overlapping but not identical. Wlds is a fusion protein that slows WD;
422 it confers a protective effect from degeneration in animal models of progressive motor
423 neuropathy and PD, but does not ameliorate in ALS model [84–86]. These findings
424 suggest that each pathological protein causes axonal degeneration by a different
425 mechanism, but the detailed molecular mechanisms are still poorly understood. However,
426 by using our method, it is anticipated that research focusing on axon degeneration will be
427 facilitated, thereby enabling the elucidation of the pathological mechanism of axonal
428 degeneration by the causative genes of ND and WD. In turn, a better understanding of the
429 underlying molecular mechanisms of axonal degeneration is promising for developing
430 therapies that inhibit or delay the onset of ageing, NDs and WD.

431 By using deep learning, it was possible to automatically create a mask that
432 extracts axon terminals from a confocal z-stack image. The image processing capabilities
433 afforded by machine learning are powerful, and recently, many quantitative and
434 segmentation methods using machine learning have been published [87–90]. MeDUsA is
435 a Python-based method specifically designed to count axons; however, it only quantifies
436 the presence of axons and does not capture pre-degenerative signs such as swelling or
437 fragmentation of axon terminals. Such changes are currently more precisely captured only
438 with a manual method [34]. An important future step will be to extend MeDUsA to
439 perform a more comprehensive quantitative analysis of morphological and cell biological
440 properties, such as the size and shape of axonal termini, the number or organisation of
441 pre-synapses, of mitochondria or other organelles in axonal terminals, to enable more
442 detailed studies of pathological mechanisms of ND.

443

444 **Conclusions:**

445 In this study, we developed MeDUsA for automatically quantifying the number of axons
446 in retinal R7 neurons in *Drosophila* with high reliability and robustness. It combines pre-
447 trained deep-learning models with a Python-based quantification system. Using our easy-
448 to-use software, we demonstrated the causative proteins of NDs actually caused the
449 axonal degeneration. We also confirmed that the severity of REP and axonal number were
450 not significantly correlated. MeDUsA is a valuable tool for the unbiased and rapid
451 quantification of axonal degeneration in genetic or pharmacological modifier screening
452 using *Drosophila* as a model.

453

454 **Materials and Methods:**

455 ***Fly Strains***

456 Flies were maintained at 25°C on standard fly food. Female flies were used in all
457 experiments except for those shown in Figure 1 to adjust the number of retinal axons.
458 *40D-UAS* (VDRC ID 60101) was obtained from the Vienna *Drosophila* Resource Center
459 (VDRC) in Vienna, Austria. *GMR-Gal4 (III)* (#8121), *Rh6-Gal4* (#7459), *Brp-FSF-GFP*
460 (#55753), *UAS-myr-RFP* (#7119), *UAS-SNCA* (#8146), *UAS-SNCA^{A53T}* (#8148), *UAS-*
461 *Tau^{S2A}* (#51364), *tub-Gal80^{TS}* (#7017 and #7019), *UAS-marf RNAi* (#55189), *UAS-opal*
462 *RNAi* (#32358), *GMR-w-RNAi* (#32067), *lexAop-syb-spGFP1-10*, *UAS-CD4-spGFP11*
463 (#64315) and 99 strains for RNAi screening were obtained from the Bloomington
464 *Drosophila* Stock Center (BDSC, Bloomington, IN, USA). Details are provided in Sup.
465 Table 1. *GMR-Gal4(II)* [37,38] was used for the expression of transgenes in the
466 photoreceptors. *Rh4-LexA* was generated previously [91]. *ortC2b-Gal4* was gifted by Dr.
467 Chi-Hon Lee [92], and *Sens-flippase* [93] was kindly provided by Dr. S. L. Zipursky.
468 *UAS-Tau* [5] and *UAS-Tau^{R406W}* [5] were gifted by Dr. M. B. Feany. *UAS-HTT^{Q0}* [94] and
469 *UAS-HTT^{Q128}* [94] were graciously given by the Dr. J. T. Littleton. *UAS-TDP-43(strong)*,
470 *UAS-TDP-43^{A315T}*, and *UAS-TDP43^{G298S}* were described previously [39,95].

471

472 ***Immunohistochemistry and imaging***

473 Immunohistochemistry and sample preparation were performed as described previously
474 [34,40]. The following antibodies were used: mouse anti-Chaoptin (24B10, 1:25;
475 Developmental Studies Hybridoma Bank, Iowa City, IA, USA), anti-mouse Alexa Fluor
476 488 (1:400; Thermo Fisher Scientific) and anti-mouse Alexa Fluor 568 (1:400; Thermo
477 Fisher Scientific). The insect pins were used because they are 0.1 mm in diameter and fit
478 the thickness of a fly brain. A coverslip was added and slides were mounted using

479 Vectashield mounting medium (Vector Laboratories). Images were captured using a
480 FV3000 confocal microscope (Olympus, Tokyo, Japan). We then obtained brain images
481 using a confocal microscope set to a 60× immersion objective (1.4 numerical aperture)
482 and a 1× digital zoom. During the scan, we set the step size to 1 μm and generated 60–90
483 optical sections of the second optic ganglion medulla, including all R7 axon terminals.
484 They are for the images shown in Figure 2, 3 and 6. In Figure 1, samples were scanned
485 using an A1 confocal microscope (Nikon, Tokyo, Japan). Images were processed using
486 either IMARIS 9.6.0 (Bitplane) or Fiji software, which is an open-source image analysis
487 software [96].

488

489 ***Eye imaging using bright-field microscopy and quantification of morphological eye***
490 ***defects***

491 For light microscopy imaging of adult eyes, 1- to 3-day-old flies, which were reared at
492 29°C for the expression of αSyn, Tau and HTT and at 25°C for the expression of TDP-
493 43, were immobilised by freezing at –20°C, and separated fly heads were mounted on
494 labelling tape (Shamrock Labels, IL, USA). The flies were then imaged using an OM-D
495 E-M5 digital camera (Olympus) and SZX16 microscope with 6.3× magnification
496 (Olympus). About 20 photographs were taken with the focus shifted slightly from the
497 centre of the eye to the edges. Each slice was depth-synthesised using Photoshop CC 2017
498 (Adobe). The edges of the eyes were then trimmed and processed using Flynotyper 1.0 to
499 quantitatively assess morphological defects in *Drosophila* eye [24].

500

501 ***Combined rough eye and axonal degeneration phenotype screening***

502 First, candidate genes for screening were selected as the phenotype in the QuickSearch
503 of FlyBase (<https://flybase.org/>) and searched for ‘synapse’ in the ‘Tissue/cell affected’
504 category. The 401 genes hit using this method were further narrowed down using settings
505 of ‘Higher’ and ‘Moderately High’ with ‘Adult Head’ in the modENCODE Expression
506 Data of FlyBase, and 99 genes available for RNAi lines at the BDSC were selected as
507 candidate genes.

508 For the initial screening, we searched to identify a factor that suppressed REP
509 to serve as an indicator of neurodegeneration. In this study, we used a transgene of TDP-
510 43^{G298S} expressed by the eye-specific *GMR-Gal4* driver to induce REP. We then
511 evaluated each RNAi line of the candidate genes, and the genes in which REP was
512 suppressed were selected. We then imaged the compound eyes of *Drosophila* using an
513 EOS Kiss X4 digital camera (Canon, Tokyo, Japan) and MZ FLIII fluorescence stereo
514 microscope (Leica, Wetzlar, Germany).

515 Next, as the second screening, R8 axons were visualised to further narrow the
516 candidate factors based on the ability to recover from axonal degeneration. To achieve
517 this, myrRFP was expressed using the *Rh6-Gal4* driver. The genotype was *Sens-*
518 *flippase/+; Rh6-Gal4/UAS-TDP-43^{G298S}; Brp-FSF-GFP, UAS-myr-RFP/UAS-RNAi*.
519 Knockdown was performed on 15 candidate genes that suppressed the REP, and the axons
520 were observed using an A1 confocal microscope (Nikon).

521

522 ***Training set generation***

523 To quantify both normal and degenerated axons with sufficient accuracy, we used
524 samples with phenotypes of axonal degeneration induced by either light stimulation or
525 mitochondrial dysfunction for machine learning.

526 *Drosophila* photoreceptors are inherently sensory neurons for light. We found
527 that constant light stimulation caused progressive axonal degeneration [34]. Taking
528 advantage of this phenomenon, we used samples of various time points under constant
529 light from normal states to severe axonal degeneration for machine learning. In detail,
530 experimental samples at 1 (n = 16), 3 (n = 16), 5 (n = 20), 7 (n = 16), 9 (n = 14), 11 (n =
531 14) and 13 days (n = 13) under constant light were used. Samples (n = 10 and n = 19)
532 were used on day 1 and day 13 in a 12-h light/dark cycle as controls, respectively. The
533 genotype was *GMR-w-RNAi/w-; lexAop-syb-spGFP1-10, UAS-CD4-spGFP11/ Rh4-*
534 *LexA; ortC2b-Gal4/+*.

535 For machine learning, we also induced photoreceptor axonal degeneration by
536 knocking down Marf or Opal, both of which are required for mitochondrial fusion. The
537 genotypes were *GMR-Gal4/40D-UAS; tub-Gal80^{ts}/+* (n = 6), *GMR-Gal4/UAS-marf*
538 *RNAi; tub-Gal80^{ts}/+* (n = 9) and *GMR-Gal4/tub-Gal80^{ts}; UAS-opal RNAi/+* (n = 20).
539 The flies were reared in a permissive temperature (20°C), and after eclosion, knockdown
540 was induced by rearing the flies in a restrictive temperature (29°C) and were dissected 4
541 weeks later. Samples reared under control conditions at 20°C for 4 weeks after eclosion
542 were also used for machine learning. The genotypes were *GMR-Gal4/40D-UAS; tub-*
543 *Gal80^{ts}/+* (n = 14), *GMR-Gal4/UAS-marf RNAi; tub-Gal80^{ts}/+* (n = 20), and *GMR-*
544 *Gal4/tub-Gal80^{ts}; UAS-opal RNAi/+* (n = 10).

545 All samples were scanned using a confocal microscope. We then manually
546 created a mask covering the axonal terminal and used the scanning data and the mask as
547 a training set.

548

549 ***Surface mask prediction and axon terminal detection***

550 A variant of 2D-U-Net was used for surface mask prediction. The original images were
551 $N \times 512 \times 512$ in size for each sample, and for each z-slice, the image before and after it
552 ($z - 1$, z and $z + 1$) were combined to form the $N \times 512 \times 512 \times 3$ size. As the terminal
553 slice does not have $z - 1$ or $z + 1$, a blank image was used instead. For training, we used
554 mask images of size $N \times 512 \times 512 \times 3$, and for inference, we obtained mask prediction
555 images of size $N \times 512 \times 512$ by discarding the channels corresponding to each $z - 1$
556 and $z + 1$ from the $N \times 512 \times 512 \times 3$ output and retaining only z . As post-processing,
557 opening and closing operations were used to exclude small blobs and to fill in holes. Then,
558 from the original image, only the area corresponding to the obtained surface mask image
559 was extracted. To detect the axon terminal, the background image was first created by
560 morphological reconstruction and then filtered regional maxima by subtracting it from
561 the original image to remove the background. Next, the image was binarised by adaptive
562 thresholding, and 3D watershed was performed using the peak obtained by calculating
563 the Euclidean distance as a seed. Finally, blobs below 20 voxels were excluded. These
564 processes were calculated using Python (v3.6.7), NumPy (v1.17.3), TensorFlow (v1.13.2),
565 scikit-image (v0.16.2), SciPy (v1.3.2) and OpenCV (v4.2.0).

566

567 *Experimental design and statistical analyses*

568 Experimental analyses were performed using Prism 8 (GraphPad Software, San Diego,
569 CA, USA). All quantifications were performed by experimenters who were blind to the
570 genotype. Data were analysed using multiple comparison ANOVA with Tukey–Kramer
571 post hoc tests or unpaired t-test with Mann–Whitney test, as noted in the Results section.
572 The null hypothesis was rejected at a 0.05 level of significance.

573

574 **List of Abbreviations:**

575 MeDUsA: a method for quantification of degeneration using fly axons

576 ND: Neurodegenerative disease

577 REP: rough eye phenotype

578 SCA3: Spinocerebellar ataxia type 3

579 PD: Parkinson's disease

580 ALS: amyotrophic lateral sclerosis

581 CNN: convolutional neural network

582 RNAi: RNA interference

583 SCA31: spinocerebellar ataxia type 31

584 FTLT: frontotemporal lobar degeneration

585 WD: Wallerian degeneration

586

587 **Declarations**

588 Ethics approval and consent to participate

589 Not applicable

590

591 **Consent for publication**

592 Not applicable

593

594 **Availability of data and materials**

595 The software documentation for MeDUsA can be found at

596 <https://github.com/SugieLab/MeDUsA>.

597 The datasets used and/or analyzed during the current study are available from the
598 corresponding authors on reasonable request.

599

600 **Competing interests**

601 The authors declare that we have no competing interests.

602

603 **Funding**

604 This work was supported in part by grants from the Ministry of Education, Culture,
605 Sports, Science and Technology of Japan (#18K14835, #18J00367 and #21K15619 to
606 YNI, #21K06184 to SHS, #17H05699 to YNA, #16H06457 and #21H02483 to TS,
607 #17H04983, #19K22592 and #21H02837 to AS), grants for Strategic Research Program
608 for Brain Sciences from Japan Agency for Medical Research and Development, Japan
609 (#JP20dm0107061 to YNA), Takeda Science Foundation Takeda Visionary Research
610 Grant to T.S., and Takeda science foundation life science research grant to AS. DZNE
611 core funding to G.T.

612

613 **Authors' contributions**

614 YNI and AS designed and organized the study.

615 YNI and AS performed immunohistochemistry, and eye imaging.

616 YNI, AS and KD performed data analysis.

617 HK established the software.

618 JO, SHS, and TS designed the screen experiment and JO performed the experiment and
619 data analysis.

620 YNA generated transgenic flies.

621 YNI, HK, KD, GT and AS wrote the manuscript

622 All authors read and approved the final manuscript.

623

624 **Acknowledgements**

625 We would like to acknowledge that Dr. Zipursky, Dr. Feany, Dr. Lee and Dr. Littleton
626 have provided us with transgenic fly strains. We would like to thank Ms. Nozaki for
627 helping us to quantify REP.

628

629 **Figure Legends:**

630 **Figure 1. Rough eye and axonal degeneration phenotypes for evaluating**
631 **neurodegeneration.**

632 (A) Dorsal schematic of the visual system in *Drosophila*. The axons of photoreceptors
633 R7 and R8 project from the retina through the lamina to the medulla. (B) The process of
634 exploring factors that mitigate TDP-43 toxicity using a combination of rough eye and
635 axonal degeneration phenotypic observations. (C) Candidate genes that suppress the
636 rough eye phenotype (REP) and their involvement in axonal toxicity. In knockdown
637 screening, six genes suppressed REP and eight genes mildly suppressed it. However, the
638 degree of REP and severity of R axon degeneration were not consistent. Yellow arrows
639 indicate fragmented axons. Scale bar = 20 μm . (D) Quantification of the ratio of axonal
640 degeneration. *** $p < 0.001$. Chi-square test was performed between the control and each
641 knockdown.

642

643 **Figure 2. Sample Preparation and Processing flow of MeDU_sA.**

644 (A) Schematic of the visual system in *Drosophila*. (B) All R7 and R8 axon terminals
645 projecting to the medulla. R axons were stained with anti-Chaoptin, which is a
646 photoreceptor-specific antibody (green). Scale bar = 20 μm . (C) Process flow of
647 generating a surface mask. First, for each slice of the z-stack image, three slices ($z - 1$,
648 z and $z + 1$) are merged by adding the previous and next slice to create an RGB image.
649 The RGB image is inputted into the training model to generate the RGB mask. Finally,
650 only the channel corresponding to the central slice is extracted to obtain the final mask.
651 (D) Process for axon terminal detection. Using the obtained surface mask stack and
652 original image stack, the surface mask region is extracted from the original image for
653 each slice, and only the signal at the axon end is extracted. Axon terminals are then
654 detected and quantified from the obtained 3D volume.

655

656 **Figure 3. Toxicity evaluation of representative ND causative factors using MeDUsA.**

657 (A–J) The R axon terminals stained with anti-Chaoptin and extracted using MeDUsA.

658 (A) Control and photoreceptor expression of (B) $\alpha\text{Syn}^{\text{WT}}$, (C) $\alpha\text{Syn}^{\text{A53T}}$, (D) Tau^{WT} , (E)
659 $\text{Tau}^{\text{R406W}}$, (F) Tau^{S2A} , (G) $\text{TDP-43}^{\text{WT}}$, (H) $\text{TDP-43}^{\text{A315T}}$, (I) HTT^{Q0} and (J) HTT^{Q128} . Scale
660 bar = 20 μm . (K) The number of axons expressing each pathogenic factor was predicted.

661 **** $p < 0.0001$, *** $p < 0.001$ and ns ($p > 0.05$). Data were analysed using multiple
662 comparison ANOVA with Tukey–Kramer *post hoc* tests. Error bars show the standard
663 error of the mean.

664

665 **Figure 4. Comparison between manual quantification and the MeDUsA system.**

666 (A) The axonal numbers quantified by manual measurements using the same dataset
667 shown in Figure 3K. **** $p < 0.00001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ and ns ($p >$

668 0.05). Data were analysed using multiple comparison ANOVA with Tukey–Kramer post
669 hoc tests. Error bars show the standard error of the mean. (B) The ratio of the axonal
670 number predicted by MeDUsA to those measured manually for each genotype. (C) The
671 correlation between the individual values measured manually and the individual values
672 predicted by MeDUsA. (D) The correlation between the average of each genotype
673 measured manually versus those predicted by MeDUsA. R^2 , coefficient of determination.
674

675 **Figure 5. Ectopic expression of causative genes of NDs in fly eye causing REP, but**
676 **inconsistent with axonal degeneration.**

677 (A–J) Representative bright-field microscope images of (A) control or fly eyes
678 overexpressing (B) SNCA^{WT}, (C) SNCA^{A53T}, (D) Tau^{WT}, (E) Tau^{R406W}, (F) Tau^{S2A}, (G)
679 TDP-43^{WT}, (H) TDP-43^{A315T}, (I) HTT^{Q0} and (J) HTT^{Q128} using the GMR-Gal4 driver. (K)
680 Graph representing the phenotypic score (P score) of each genotype calculated using
681 Flynotyper. **** $p < 0.0001$, ** $p < 0.01$ and ns ($p > 0.05$). Data were analysed using
682 multiple comparison ANOVA with Tukey–Kramer *post hoc* tests. Error bars show the
683 standard error of the mean.

684

685 **Reference**

686

687 1. Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. Csh Perspect
688 Biol. 2017;9:a028035.

- 689 2. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, et al.
690 Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural
691 Degeneration in *Drosophila*. *Cell*. 1998;93:939–49.
- 692 3. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, et al.
693 Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of
694 *Drosophila* Photoreceptor Neurons. *Neuron*. 1998;21:633–42.
- 695 4. Feany MB, Bender WW. A *Drosophila* model of Parkinson’s disease. *Nature*.
696 2000;404:394–8.
- 697 5. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al.
698 Tauopathy in *Drosophila*: neurodegeneration without neurofibrillary tangles. *Science*.
699 2001;293:711–4.
- 700 6. Chouhan AK, Guo C, Hsieh Y-C, Ye H, Senturk M, Zuo Z, et al. Uncoupling
701 neuronal death and dysfunction in *Drosophila* models of neurodegenerative disease.
702 *Acta Neuropathologica Commun*. 2016;4:62.
- 703 7. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2
704 intermediate-length polyglutamine expansions are associated with increased risk for
705 ALS. *Nature*. 2010;466:1069–75.
- 706 8. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates
707 and generating dominant phenotypes. *Development*. 1993;118:401–15.

- 708 9. Blard O, Feuillet S, Bou J, Chaumette B, Frébourg T, Campion D, et al.
709 Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in
710 *Drosophila*. *Hum Mol Genet.* 2007;16:555–66.
- 711 10. Chen X, Li Y, Huang J, Cao D, Yang G, Liu W, et al. Study of tauopathies by
712 comparing *Drosophila* and human tau in *Drosophila*. *Cell Tissue Res.* 2007;329:169–
713 78.
- 714 11. Ambegaokar SS, Jackson GR. Functional genomic screen and network analysis
715 reveal novel modifiers of tauopathy dissociated from tau phosphorylation. *Hum Mol*
716 *Genet.* 2011;20:4947–77.
- 717 12. M'Angale PG, Staveley BE. The Bcl-2 homologue Buffy rescues α -synuclein-
718 induced Parkinson disease-like phenotypes in *Drosophila*. *Bmc Neurosci.* 2016;17:24.
- 719 13. Alexopoulou Z, Lang J, Perrett RM, Elschami M, Hurry MED, Kim HT, et al.
720 Deubiquitinase Usp8 regulates α -synuclein clearance and modifies its toxicity in Lewy
721 body disease. *Proc National Acad Sci.* 2016;113:E4688–97.
- 722 14. Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, et al. Enhanced
723 ubiquitin-dependent degradation by Nedd4 protects against α -synuclein accumulation
724 and toxicity in animal models of Parkinson's disease. *Neurobiol Dis.* 2014;64:79–87.
- 725 15. Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N, et al. VPS35
726 dysfunction impairs lysosomal degradation of α -synuclein and exacerbates
727 neurotoxicity in a *Drosophila* model of Parkinson's disease. *Neurobiol Dis.* 2014;71:1–
728 13.

- 729 16. Zhan L, Hanson KA, Kim SH, Tare A, Tibbetts RS. Identification of Genetic
730 Modifiers of TDP-43 Neurotoxicity in *Drosophila*. *Plos One*. 2013;8:e57214.
- 731 17. Kim H-J, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, et al.
732 Therapeutic modulation of eIF2 α phosphorylation rescues TDP-43 toxicity in
733 amyotrophic lateral sclerosis disease models. *Nat Genet*. 2014;46:152–60.
- 734 18. Calpena E, Amo VL del, Chakraborty M, Llamusi B, Artero R, Espinós C, et al. The
735 *Drosophila* junctophilin gene is functionally equivalent to its four mammalian
736 counterparts and is a modifier of a Huntingtin poly-Q expansion and the Notch
737 pathway. *Dis Model Mech*. 2017;11:dmm029082.
- 738 19. Kaltenbach LS, Orr H, Romero E, Becklin RR, Chettier R, Bell R, et al. Huntingtin
739 interacting proteins are genetic modifiers of neurodegeneration. *PLoS Genetics*.
740 2007;3:e82.
- 741 20. Doumanis J, Wada K, Kino Y, Moore AW, Nukina N. RNAi Screening in
742 *Drosophila* Cells Identifies New Modifiers of Mutant Huntingtin Aggregation. *Plos*
743 *One*. 2009;4:e7275.
- 744 21. Shim K-H, Kim S-H, Hur J, Kim D-H, Demirev AV, Yoon S-Y. Small-molecule
745 drug screening identifies drug Ro 31-8220 that reduces toxic phosphorylated tau in
746 *Drosophila melanogaster*. *Neurobiol Dis*. 2019;130:104519.
- 747 22. Lin Y, Xue J, Deng J, He H, Luo S, Chen J, et al. Neddylation activity modulates
748 the neurodegeneration associated with fragile X associated tremor/ataxia syndrome
749 (FXTAS) through regulating Sima. *Neurobiol Dis*. 2020;143:105013.

- 750 23. Diez-Hermano S, Valero J, Rueda C, Ganfornina MD, Sanchez D. An automated
751 image analysis method to measure regularity in biological patterns: a case study in a
752 *Drosophila* neurodegenerative model. *Molecular neurodegeneration*. 2015;10:9.
- 753 24. Iyer J, Wang Q, Le T, Pizzo L, Grönke S, Ambegaokar SS, et al. Quantitative
754 Assessment of Eye Phenotypes for Functional Genetic Studies Using *Drosophila*
755 *melanogaster*. *G3 (Bethesda, Md)*. 2016;6:1427–37.
- 756 25. McGurk L, Berson A, Bonini NM. *Drosophila* as an In Vivo Model for Human
757 Neurodegenerative Disease. *Genetics*. 2015;201:377–402.
- 758 26. Bhattacharya MRC, Gerdtts J, Naylor SA, Royse EX, Ebstein SY, Sasaki Y, et al. A
759 model of toxic neuropathy in *Drosophila* reveals a role for MORN4 in promoting
760 axonal degeneration. *Journal of Neuroscience*. 2012;32:5054–61.
- 761 27. Sreedharan J, Neukomm LJ, Brown RH, Freeman MR. Age-Dependent TDP-43-
762 Mediated Motor Neuron Degeneration Requires GSK3, hat-trick, and xmas-2. *Curr*
763 *Biol*. 2015;25:2130–6.
- 764 28. Moen E, Bannon D, Kudo T, Graf W, Covert M, Valen DV. Deep learning for
765 cellular image analysis. *Nat Methods*. 2019;16:1233–46.
- 766 29. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical
767 Image Segmentation. *Lect Notes Comput Sc*. 2015;234–41.
- 768 30. Çiçek Ö, Abdulkadir A, Lienkamp SS, Brox T, Ronneberger O. 3D U-Net: Learning
769 Dense Volumetric Segmentation from Sparse Annotation. *Medical Image Computing*

- 770 and Computer-Assisted Intervention – MICCAI 2016, 19th International Conference,
771 Athens, Greece, October 17-21, 2016, Proceedings, Part II. 2016. p. 424–32.
- 772 31. Falk T, Mai D, Bensch R, Çiçek Ö, Abdulkadir A, Marrakchi Y, et al. U-Net: deep
773 learning for cell counting, detection, and morphometry. *Nat Methods*. 2019;16:67–70.
- 774 32. Fischer CA, Besora-Casals L, Rolland SG, Haeussler S, Singh K, Duchon M, et al.
775 MitoSegNet: Easy-to-use Deep Learning Segmentation for Analyzing Mitochondrial
776 Morphology. *iScience*. 2020;23:101601.
- 777 33. Long F. Microscopy cell nuclei segmentation with enhanced U-Net. *Bmc*
778 *Bioinformatics*. 2020;21:8.
- 779 34. Richard M, Doubková K, Nitta Y, Kawai H, Sugie A, Tavosanis G. A quantitative
780 model of sporadic axonal degeneration in the *Drosophila* visual system. *bioRxiv*. 2021;
- 781 35. Sang T-K, Jackson GR. *Drosophila* models of neurodegenerative disease. *Neurorx*.
782 2005;2:438–46.
- 783 36. Deerlin VMV, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al.
784 TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a
785 genetic and histopathological analysis. *Lancet Neurology*. 2008;7:409–16.
- 786 37. Newsome TP, Asling B, Dickson BJ. Analysis of *Drosophila* photoreceptor axon
787 guidance in eye-specific mosaics. *Development*. 2000;127:851–60.

- 788 38. Newsome TP, Schmidt S, Dietzl G, Keleman K, Asling B, Debant A, et al. Trio
789 combines with dock to regulate Pak activity during photoreceptor axon pathfinding in
790 *Drosophila*. *Cell*. 2000;101:283–94.
- 791 39. Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A, et al.
792 Regulatory Role of RNA Chaperone TDP-43 for RNA Misfolding and Repeat-
793 Associated Translation in SCA31. *Neuron*. 2017;94:108-124.e7.
- 794 40. Sugie A, Möhl C, Hakeda-Suzuki S, Matsui H, Suzuki T, Tavosanis G. Analyzing
795 Synaptic Modulation of *Drosophila melanogaster* Photoreceptors after Exposure to
796 Prolonged Light. *J Vis Exp*. 2017;
- 797 41. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α -
798 Synuclein in Lewy bodies. *Nature*. 1997;388:839–40.
- 799 42. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al.
800 Mutation in the α -Synuclein Gene Identified in Families with Parkinson's Disease.
801 *Science*. 1997;276:2045–7.
- 802 43. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association
803 of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.
804 *Nature*. 1998;393:702–5.
- 805 44. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-
806 43 A315T mutation in familial motor neuron disease. *Ann Neurol*. 2008;63:535–8.

- 807 45. Chen X, Peterson J, Nachman RJ, Ganetzky B. Drosulfakinin activates CCKLR-
808 17D1 and promotes larval locomotion and escape response in *Drosophila*. *Fly*.
809 2012;6:290–7.
- 810 46. Williams MJ, Goergen P, Rajendran J, Zheleznyakova G, Hägglund MG, Perland E,
811 et al. Obesity-Linked Homologues TfAP-2 and Twz Establish Meal Frequency in
812 *Drosophila melanogaster*. *Plos Genet*. 2014;10:e1004499.
- 813 47. Agrawal P, Kao D, Chung P, Looger LL. The neuropeptide Drosulfakinin regulates
814 social isolation-induced aggression in *Drosophila*. *J Exp Biol*. 2020;223:jeb207407.
- 815 48. Wu F, Deng B, Xiao N, Wang T, Li Y, Wang R, et al. A neuropeptide regulates
816 fighting behavior in *Drosophila melanogaster*. *Elife*. 2020;9:e54229.
- 817 49. Chen X, Ganetzky B. A neuropeptide signaling pathway regulates synaptic growth
818 in *Drosophila*. *J Cell Biol*. 2012;196:529–43.
- 819 50. Fogarty MJ, Klenowski PM, Lee JD, Driberg-Thompson JR, Bartlett SE, Ngo ST,
820 et al. Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43
821 model of amyotrophic lateral sclerosis. *Sci Rep-uk*. 2016;6:37968.
- 822 51. Jiang T, Handley E, Brizuela M, Dawkins E, Lewis KEA, Clark RM, et al.
823 Amyotrophic lateral sclerosis mutant TDP-43 may cause synaptic dysfunction through
824 altered dendritic spine function. *Dis Model Mech*. 2019;12:dmm038109.
- 825 52. Breen TR, Lucchesi JC. Analysis of the dosage compensation of a specific transcript
826 in *Drosophila melanogaster*. *Genetics*. 1986;112:483–91.

- 827 53. Freibaum BD, Chitta RK, High AA, Taylor JP. Global Analysis of TDP-43
828 Interacting Proteins Reveals Strong Association with RNA Splicing and Translation
829 Machinery. *J Proteome Res.* 2010;9:1104–20.
- 830 54. Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. Amyotrophic Lateral Sclerosis-
831 associated Proteins TDP-43 and FUS/TLS Function in a Common Biochemical
832 Complex to Co-regulate HDAC6 mRNA*. *J Biol Chem.* 2010;285:34097–105.
- 833 55. Ling S-C, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, et al.
834 ALS-associated mutations in TDP-43 increase its stability and promote TDP-43
835 complexes with FUS/TLS. *Proc National Acad Sci.* 2010;107:13318–23.
- 836 56. Wang J-W, Brent JR, Tomlinson A, Shneider NA, McCabe BD. The ALS-
837 associated proteins FUS and TDP-43 function together to affect *Drosophila* locomotion
838 and life span. *J Clin Invest.* 2011;121:4118–26.
- 839 57. Kabashi E, Bercier V, Lissouba A, Liao M, Brustein E, Rouleau GA, et al. FUS and
840 TARDBP but Not SOD1 Interact in Genetic Models of Amyotrophic Lateral Sclerosis.
841 *Plos Genet.* 2011;7:e1002214.
- 842 58. Lee S, Wang J-W, Yu W, Lu B. Phospho-dependent ubiquitination and degradation
843 of PAR-1 regulates synaptic morphology and tau-mediated A β toxicity in *Drosophila*.
844 *Nature Communications.* 2012;3:1312–12.
- 845 59. Burré J, Sharma M, Südhof TC. Cell Biology and Pathophysiology of α -Synuclein.
846 *Csh Perspect Med.* 2018;8:a024091.

- 847 60. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al.
848 Axonal α -synuclein aggregates herald centripetal degeneration of cardiac sympathetic
849 nerve in Parkinson's disease. *Brain*. 2008;131:642–50.
- 850 61. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al.
851 Exogenous α -Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic
852 Dysfunction and Neuron Death. *Neuron*. 2011;72:57–71.
- 853 62. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α -synuclein:
854 from structure and toxicity to therapeutic target. *Nature Publishing Group*. 2013;14:38–
855 48.
- 856 63. Kouroupi G, Taoufik E, Vlachos IS, Tsioras K, Antoniou N, Papastefanaki F, et al.
857 Defective synaptic connectivity and axonal neuropathology in a human iPSC-based
858 model of familial Parkinson's disease. *Proc National Acad Sci*. 2017;114:E3679–88.
- 859 64. Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-
860 synuclein oligomers: a new hope. *Acta Neuropathologica*. 2017;134:819–38.
- 861 65. Kolarova M, García-Sierra F, Bartos A, Rigny J, Ripova D. Structure and Pathology
862 of Tau Protein in Alzheimer Disease. *Int J Alzheimer's Dis*. 2012;2012:731526.
- 863 66. Dayanandan R, Slegtenhorst MV, Mack TGA, Ko L, Yen S-H, Leroy K, et al.
864 Mutations in tau reduce its microtubule binding properties in intact cells and affect its
865 phosphorylation. *Febs Lett*. 1999;446:228–32.

- 866 67. Miyasaka T, Morishima-Kawashima M, Ravid R, Heutink P, Swieten JC van,
867 Nagashima K, et al. Molecular Analysis of Mutant and Wild-Type Tau Deposited in the
868 Brain Affected by the FTDP-17 R406W Mutation. *Am J Pathology*. 2001;158:373–9.
- 869 68. Ikeda M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, et al.
870 Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W
871 Transgenic Mice. *Am J Pathology*. 2005;166:521–31.
- 872 69. Nakamura M, Shiozawa S, Tsuboi D, Amano M, Watanabe H, Maeda S, et al.
873 Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W
874 Tau Mutation in Patient-Derived iPSCs. *Stem Cell Rep*. 2019;13:684–99.
- 875 70. Jackson GR, Wiedau-Pazos M, Sang T-K, Wagle N, Brown CA, Massachi S, et al.
876 Human Wild-Type Tau Interacts with wingless Pathway Components and Produces
877 Neurofibrillary Pathology in *Drosophila*. *Neuron*. 2002;34:509–19.
- 878 71. Povellato G, Tuxworth RI, Hanger DP, Tear G. Modification of the *Drosophila*
879 model of in vivo Tau toxicity reveals protective phosphorylation by GSK3 β . *Biol Open*.
880 2013;3:1–11.
- 881 72. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al.
882 Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral
883 Sclerosis. *Science*. 2006;314:130–3.
- 884 73. Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular Mechanisms
885 of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. *Front Mol*
886 *Neurosci*. 2019;12:25.

- 887 74. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, et al. Gain and
888 loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits
889 in vivo. *Hum Mol Genet.* 2010;19:671–83.
- 890 75. Xu Y-F, Gendron TF, Zhang Y-J, Lin W-L, D’Alton S, Sheng H, et al. Wild-Type
891 Human TDP-43 Expression Causes TDP-43 Phosphorylation, Mitochondrial
892 Aggregation, Motor Deficits, and Early Mortality in Transgenic Mice. *J Neurosci.*
893 2010;30:10851–9.
- 894 76. Ash PEA, Zhang Y-J, Roberts CM, Saldi T, Hutter H, Buratti E, et al. Neurotoxic
895 effects of TDP-43 overexpression in *C. elegans*. *Hum Mol Genet.* 2010;19:3206–18.
- 896 77. Diaper DC, Adachi Y, Sutcliffe B, Humphrey DM, Elliott CJH, Stepto A, et al. Loss
897 and gain of *Drosophila* TDP-43 impair synaptic efficacy and motor control leading to
898 age-related neurodegeneration by loss-of-function phenotypes. *Hum Mol Genet.*
899 2013;22:1539–57.
- 900 78. Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, et al. A *Drosophila* model for TDP-43
901 proteinopathy. *Proc National Acad Sci.* 2010;107:3169–74.
- 902 79. Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-associated mutation
903 affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. *Nat*
904 *Struct Mol Biol.* 2011;18:822–30.
- 905 80. Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. Wild-type
906 and A315T mutant TDP-43 exert differential neurotoxicity in a *Drosophila* model of
907 ALS. *Hum Mol Genet.* 2011;20:2308–21.

- 908 81. Roos RA. Huntington's disease: a clinical review. *Orphanet J Rare Dis.* 2010;5:40.
- 909 82. Gatto RG, Chu Y, Ye AQ, Price SD, Tavassoli E, Buenaventura A, et al. Analysis
910 of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and
911 increased vulnerability of callosal axons in Huntington's disease. *Hum Mol Genet.*
912 2015;24:5285–98.
- 913 83. Zhang S, Binari R, Zhou R, Perrimon N. A Genomewide RNA Interference Screen
914 for Modifiers of Aggregates Formation by Mutant Huntingtin in *Drosophila*. *Genetics.*
915 2010;184:1165–79.
- 916 84. Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC. Inhibiting Axon
917 Degeneration and Synapse Loss Attenuates Apoptosis and Disease Progression in a
918 Mouse Model of Motoneuron Disease. *Curr Biol.* 2003;13:669–73.
- 919 85. Sajadi A, Schneider BL, Aebischer P. Wlds-Mediated Protection of Dopaminergic
920 Fibers in an Animal Model of Parkinson Disease. *Curr Biol.* 2004;14:326–30.
- 921 86. Velde CV, Garcia ML, Yin X, Trapp BD, Cleveland DW. The neuroprotective
922 factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease. *Neuromol*
923 *Med.* 2004;5:193–203.
- 924 87. Haberl MG, Churas C, Tindall L, Boassa D, Phan S, Bushong EA, et al.
925 CDeep3M—Plug-and-Play cloud-based deep learning for image segmentation. *Nat*
926 *Methods.* 2018;15:677–80.

- 927 88. Diez-Hermano S, Ganformina MD, Vegas-Lozano E, Sanchez D. Machine Learning
928 Representation of Loss of Eye Regularity in a Drosophila Neurodegenerative Model.
929 Front Neurosci-switz. 2020;14:516.
- 930 89. Kayasandik CB, Ru W, Labate D. A multistep deep learning framework for the
931 automated detection and segmentation of astrocytes in fluorescent images of brain
932 tissue. Sci Rep-uk. 2020;10:5137.
- 933 90. Fogo GM, Anzell AR, Maheras KJ, Raghunayakula S, Wider JM, Emaus KJ, et al.
934 Machine learning-based classification of mitochondrial morphology in primary neurons
935 and brain. Sci Rep-uk. 2021;11:5133.
- 936 91. Berger-Müller S, Sugie A, Takahashi F, Tavosanis G, Hakeda-Suzuki S, Suzuki T.
937 Assessing the Role of Cell-Surface Molecules in Central Synaptogenesis in the
938 Drosophila Visual System. Plos One. 2013;8:e83732.
- 939 92. Gao S, Takemura S, Ting C-Y, Huang S, Lu Z, Luan H, et al. The Neural Substrate
940 of Spectral Preference in Drosophila. Neuron. 2008;60:328–42.
- 941 93. Chen Y, Akin O, Nern A, Tsui CYK, Pecot MY, Zipursky SL. Cell-type-Specific
942 Labeling of Synapses In Vivo through Synaptic Tagging with Recombination. Neuron.
943 2014;81:280–93.
- 944 94. Lee W-CM, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-
945 containing proteins and block axonal transport in a Drosophila model of Huntington’s
946 disease. P Natl Acad Sci Usa. 2004;101:3224–9.

- 947 95. Saitoh Y, Fujikake N, Okamoto Y, Popiel HA, Hatanaka Y, Ueyama M, et al. p62
948 Plays a Protective Role in the Autophagic Degradation of Polyglutamine Protein
949 Oligomers in Polyglutamine Disease Model Flies*. J Biol Chem. 2015;290:1442–53.
- 950 96. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al.
951 Fiji: an open-source platform for biological-image analysis. Nature Methods.
952 2012;9:676–82.
- 953




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5